Noven to Present at UBS Global Specialty Pharmaceuticals Conference
Posted on: Thursday, 20 April 2006, 18:00 CDT
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that Robert C. Strauss, its President, CEO & Chairman, is scheduled to provide an update on Noven's business and prospects at the UBS Global Specialty Pharmaceuticals Conference in New York on Monday, April 24, 2006, at 2:30 p.m. Eastern Time. The public is invited to listen to the presentation live via webcast at http://www.noven.com, and a replay will be available for at least two weeks at the same site.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are approved in over 30 countries, and a range of new patches are being investigated and developed in collaboration with Novartis Pharma AG, Shire plc, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See http://www.noven.com for additional information.
Source: Business Wire
Related Articles
- Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals
- Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
- Hisamitsu Pharmaceutical Announces Expiration of Initial Tender Offer Period for Outstanding Shares of Noven Pharmaceuticals and Commencement of Subsequent Offering Period
- Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
- Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
- Noven Provides Update on Daytrana(R) Methylphenidate Transdermal System
- Noven Signs License and Supply Agreements With Procter & Gamble Pharmaceuticals
- Noven & Shire to Develop New Transdermal Patch For ADHD
- Shire and Noven Announce Positive Clinical Data for Transdermal ADHD Treatment
 |
 |
User Comments (0)
RSS Feeds